Edgar Filing: Global Blood Therapeutics, Inc. - Form 4

Global Blood Therapeutics, Inc. Form 4 February 03, 2016

February 03	, 2016									
FORM	ΠΔ									PROVAL
	UNIT	ED STATES		XITIES A shington,			NGE C	COMMISSION	OMB Number:	3235-0287
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. Kather STATEMENT OF CHAI Filed pursuant to Section Section 17(a) of the Public U				GES IN E SECUR 6(a) of the illity Hold	BENEF ITIES e Securit ling Con	ICIA ties E	xchang y Act of	e Act of 1934, 1935 or Sectio	Expires: Estimated a burden hour response	-
See Instr 1(b).		30(h)	of the In	vestment	Compar	iy Ac	t of 194	40		
(Print or Type	Responses)									
Choi Jung Symbol			r Name and Ticker or Trading Blood Therapeutics, Inc.				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
THERAPE	(First) AL BLOOD UTICS, INC. URT, SUITE		3. Date of (Month/D 02/01/20	-	ansaction			Director X Officer (give below) S		Owner er (specify
	(Street)		4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
SOUTH SA FRANCISC	AN CO, CA 94080)							Iore than One Re	
(City)	(State)	(Zip)	Tabl	e I - Non-D	erivative	Secur	ities Acq	uired, Disposed of	, or Beneficial	ly Owned
1.Title of Security (Instr. 3)		Date 2A. Dee (ear) Execution any (Month/	med	3. Transactio	4. Securi m(A) or D (Instr. 3,	ties Adispose 4 and (A) or	cquired d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of
Common Stock	02/01/2016			А	749 <u>(1)</u>		\$ 16.09	168,606	D	
Reminder: Rep	port on a separate	e line for each c	lass of secu	rities benefi	cially own	ned dii	ectly or i	ndirectly.		

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Edgar Filing: Global Blood Therapeutics, Inc. - Form 4

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)			7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address		Relationships					
	Director	10% Owner	Officer	Other			
Choi Jung C/O GLOBAL BLOOD THERAPEUTICS, 400 EAST JAMIE COURT, SUITE 101 SOUTH SAN FRANCISCO, CA 94080	INC.		See Remarks				
Signatures							
/s/ John Schembri, as Attorney-in-Fact	02/03/2016						

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan.

Remarks:

Chief Business and Strategy Officer

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.